Performance of (89)Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

PURPOSE: Treatment of patients with diffuse large B cell lymphoma (DLBCL) includes rituximab, an anti-CD20 monoclonal antibody (mAb). Insufficient tumor targeting might cause therapy failure. Tumor uptake of (89)Zirconium ((89)Zr)-mAb is a potential imaging biomarker for tumor targeting, since it de...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Jauw, Yvonne W. S., Zijlstra, Josée M., de Jong, Daphne, Vugts, Danielle J., Zweegman, Sonja, Hoekstra, Otto S., van Dongen, Guus A. M. S., Huisman, Marc C.
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5218417/
https://ncbi.nlm.nih.gov/pubmed/28060891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0169828
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados